Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, in…
Biotechnology
CN, Nanjing [HQ]
Ratios
8 Sheets · From 2023 to 2012Configuration
Margins, Growth Rates In %
| Ratio | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross Margin | 82.67 | 84.84 | 82.92 | 82.36 | 80.04 | 78.40 | 79.08 | 75.43 | |
| Profit Margin | 2.73 | 9.06 | 16.25 | 19.93 | 14.85 | 30.14 | 14.73 | 10.82 | |
| Operating Margin | 4.63 | 13.72 | 20.87 | 23.26 | 12.55 | 13.76 | 13.65 | 10.77 | |
|
EPS Growth
|
- - | - - | 115.39 | 39.29 | -33.33 | 123.08 | -31.03 | -32.50 | |
| EPS CNY | 53.00 | 13.00 | 28.00 | 39.00 | 26.00 | 58.00 | 40.00 | 27.00 | |
| Return on Assets (ROA) | 1.69 | 6.75 | 11.58 | 14.83 | 6.12 | 14.83 | 8.63 | 6.59 | |
| Return on Equity (ROE) | 2.83 | 19.70 | 46.88 | 67.79 | 12.63 | 23.41 | 13.06 | 9.90 | |
| Return on Invested Capital (ROIC) | 6.12 | 12.07 | 19.16 | 24.58 | 5.43 | 9.11 | 10.45 | 7.94 | |
| Solvency | |||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 0.06 | 25.36 | 36.57 | 43.46 | 30.16 | 16.10 | 13.98 | 13.17 | |
| Debt/Equity | 0.10 | 74.06 | 148.09 | 198.65 | 62.24 | 25.41 | 21.14 | 19.79 | |
| Debt/EBITDA | -78.16 | 90.25 | 111.25 | 192.61 | 3.78 | 70.53 | -13.85 | -52.99 | |
|
Debt/Capitalization
|
0.10 | 42.55 | 59.69 | 66.52 | 38.36 | 20.26 | 17.45 | 16.52 | |
| Long-Term Debt/Capitalization | 0.10 | 14.56 | 7.18 | 46.19 | 21.70 | 1.14 | 2.14 | 4.42 | |
| Interest Debt per Share CNY | -0.74 | 0.53 | 0.91 | 1.17 | 1.32 | 0.65 | 0.59 | 0.56 | |
| Debt Growth | - - | - - | 75.91 | 26.88 | 12.21 | -50.43 | -7.89 | -5.15 | |
| Liquidity | |||||||||
| Current Ratio | 144.14 | 109.96 | 89.16 | 84.52 | 184.92 | 162.53 | 184.02 | 209.95 | |
| Quick Ratio | 134.14 | 102.57 | 83.47 | 77.28 | 177.41 | 154.86 | 173.82 | 187.07 | |
| Cash Ratio | 14.73 | 22.62 | 28.89 | 10.35 | 93.51 | 31.76 | 55.93 | 74.73 | |
| Operating Cash Flow Ratio | - - | - - | - - | - - | - - | - - | - - | - - | |
| Turnover | |||||||||
| Inventory Turnover | 298.57 | 313.13 | 329.76 | 358.01 | 342.60 | 459.26 | 437.29 | 264.20 | |
| Receivables Turnover | 190.50 | 554.16 | 474.53 | 376.74 | 240.98 | 208.43 | 270.34 | 249.86 | |
| Payables Turnover | 581.10 | 272.57 | 250.75 | 348.63 | 371.75 | 333.38 | 395.36 | 511.84 | |
|
Asset Turnover
|
61.76 | 74.45 | 71.22 | 74.43 | 41.20 | 49.20 | 58.61 | 60.88 | |
| Fixed Turnover | 247.79 | 325.93 | 323.11 | 260.36 | 205.74 | 254.87 | 290.95 | 301.50 | |
| Coverage | |||||||||
| Interest Coverage | -118.88 | 907.89 | 1,981.62 | 1,010.14 | 422.99 | 970.95 | 2,506.70 | 2,059.14 | |
| Asset Coverage | - - | 200 | 100 | 100 | 200 | 500 | 500 | 500 | |
| Cash Flow Coverage (CFGR) | 15,678.90 | 71.27 | 33.47 | 26.28 | 2.93 | -12.35 | 89.91 | 10.57 | |
| EBITDA Coverage | -200 | 1,400 | 2,100 | 1,100 | 500 | 1,300 | 3,100 | 3,100 | |
| Dividend Coverage | - - | - - | -100 | -100 | - - | -300 | -200 | -100 | |
| Time Interest Earned (TIE) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Market Prospects | |||||||||
| Dividend Yield | - - | - - | 2.19 | 3.57 | - - | 2.05 | 1.46 | 2.70 | |
| Earnings Yield | 6.01 | 1.47 | 2.92 | 3.93 | 3.41 | 7.89 | 3.47 | 4.61 | |
|
Price/Earnings (P/E)
|
1,664.82 | 6,795.62 | 3,422.24 | 2,546.54 | 2,933.70 | 1,267.28 | 2,878.15 | 2,169.28 | |
| Price/Earnings Growth (PEG) | - - | - - | 29.66 | 64.82 | -88.01 | 10.30 | -92.74 | -66.75 | |
|
Price/Book (P/B)
|
47.13 | 1,338.42 | 1,604.24 | 1,726.33 | 370.48 | 296.71 | 375.93 | 214.67 | |
| Price/Tangible Book (P/TB) | 47.13 | 1,338.42 | 1,604.24 | 1,726.33 | 370.48 | 296.71 | 375.93 | 214.67 | |
| Price/Sales (P/S) | 45.52 | 615.64 | 556.21 | 507.43 | 435.65 | 382.00 | 423.98 | 234.65 | |
|
Price/Cash Flow (P/CF)
|
302.39 | 2,535.73 | 3,236.40 | 3,307.14 | 20,305.92 | -9,456.38 | 1,977.68 | 10,265.06 | |
| Price/Free CF (P/FCF) | 394.72 | 3,681.15 | 5,698.70 | 9,639.14 | -7,669.41 | -4,641.80 | 3,959.15 | -1,870.78 | |
| Price/Operating CF (P/OCF) | 302.39 | 2,535.73 | 3,236.40 | 3,307.14 | 20,305.92 | -9,456.38 | 1,977.68 | 10,265.06 |